Non-conventional imaging technique studied

Conventional imaging techniques often do not detect the specific location of prostate cancer in men with biochemical recurrence (PSA ≥ 0.2 ng/m) following radical prostatectomy (the removal of the entire prostate gland and surrounding tissues).

A retrospective data review found that a novel imaging technique, Gallium-68 Prostate-Specific Membrane Antigen positron emission tomography (PSMA PET), detected lesions in a high proportion of men with biochemical recurrence following radical prostatectomy.

What Patients Need to Know

Many of the lesions PSMA PET detected were outside of the pelvis, areas typically not reached by post-surgery radiation. The detection of lesions, and their specific location in the body, may facilitate more precise targeting of treatment areas for men with biochemical recurrence of prostate cancer.

PARP inhibitor studied in treatment of metastatic disease

Drugs that inhibit a type of enzyme called PARP are designed to destroy cancer cells by preventing them from repairing their damaged DNA. PARP inhibition is not a standard therapy for prostate cancer. In the phase II TOPARP trial, 50 men with metastatic castration-resistant prostate cancer (mCRPC) received the PARP inhibitor olaparib, with promising results in terms of treatment response.

What Patients Need to Know

With the reporting of the TOPARP results, interest in PARP inhibitors as a potential treatment approach for a subset of men with prostate cancer has increased. However, more research is needed to prove the effectiveness and safety of this treatment approach.

PROPHECY trial confirms prognostic value of AR-47 test

Androgen receptor-signaling inhibitor (ARSi) therapy is not effective in treating all cases of mCRPC. By detecting the presence of circulating tumor cells (CTCs) that are positive for the AR-V7 protein, the AR-V7 test is designed to identify men with mCRPC who will not benefit from ARSi therapy.

What Patients Need to Know

The multicenter PROPHECY trial investigated and confirmed the prognostic value of the AR-V7 test. PROPHECY concluded that most men with mCRPC whose AR-V7 test results showed the presence of AR-V7-positive CTCs received little or no clinical benefit from ARSi therapy (either enzalutamide or abiraterone).